Key result
The 5-factor modified frailty index strongly predicted 30-day mortality after hysterectomy for both benign (c=0.819; 95% CI 0.704-0.933) and oncologic (c=0.801; 95% CI 0.750-0.851) indications.
Why the study?
The utility of the 5-factor modified frailty index had not been evaluated between benign versus gynecologic oncology patient populations.
Does the 5-factor modified frailty index (mFI-5) predict major postoperative complications, readmission, or death within 30 days of hysterectomy for benign and oncologic indications?
Cohort (n=80,293)
Does the 5-factor modified frailty index (mFI-5) predict major postoperative complications, readmission, or death within 30 days of hysterectomy for benign and oncologic indications?
Effect estimate: c-statistic 0.819 (95% CI 0.704-0.933)
The mFI-5 is a strong predictor of 30-day mortality and serious postoperative complications following hysterectomy, which may aid in preoperative risk stratification.
Background: The 5-factor modified frailty index (mFI-5) has been validated against the original 11-factor modified frailty index in gynecologic surgery, however its utility has not been evaluated between benign versus gynecologic oncology patient populations. Objective: To evaluate the predictive value of the mFI-5 in identifying women at increased risk for major postoperative complications, readmission, or death within 30 days of hysterectomy for benign and oncologic indications. Methods: Patients who underwent hysterectomy between 2015 and 2017 were identified from the NSQIP database and stratified into benign or malignant indications. Demographic and mFI-5 variables were extracted. The mFI-5 was calculated by dividing the sum of all affirmative variables by the total number of input variables in the database. Logistic regression modeling was performed adjusting for confounders. C-statistic with 95% CI was obtained post-regression. Results: 80,293 hysterectomies (59,078 benign and 21,215 oncologic) were identified. The benign group was more likely to have an mFI-5 score of 0 (70 % vs 50 %, p = 0.001) and had shorter operative times (p = 0.001). In the benign group, mFI-5 was a strong predictor of mortality (c = 0.819, CI 0.704-0.933). Within the oncology group, the mFI-5 was a strong predictor of mortality (c = 0.801, CI 0.750-0.851), particularly for uterine and cervical cancers. It was moderately predictive of readmission (c = 0.671, CI 0.656-0.686) and strongly predictive of Clavien-Dindo class III and IV complications (c = 0.732, CI 0.713-0.750). Conclusion: The mFI-5 is a strong predictor of 30-day mortality and serious postoperative complications. These findings have the potential to improve identification of high-risk patients in the preoperative setting.
No takes yet. Share an insight, caveat, or question.
Hermann et al. (2022) conducted a cohort in Hysterectomy for benign and oncologic indications (n=80,293). 5-factor modified frailty index (mFI-5) was evaluated on 30-day mortality (c-statistic 0.819, 95% CI 0.704-0.933). The 5-factor modified frailty index strongly predicted 30-day mortality after hysterectomy for both benign (c=0.819; 95% CI 0.704-0.933) and oncologic (c=0.801; 95% CI 0.750-0.851) indications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: